Results 1 to 10 of about 103,961 (275)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. [PDF]

PLoS ONE, 2018
OBJECTIVES:The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated.
Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, Yuki Hosono, Saeko Nakatsubo, Kohei Nishida, Nobuyuki Sawa, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori   +12 more
doaj   +1 more source

Severe lichenoid eruption due to concomitant medications following nivolumab administration

JEADV Clinical Practice, 2023
Recently, immune checkpoint inhibitors have been administered for several cancers and have shown great efficacy. However, they are associated with various immune‐related adverse events.
Risa Kakuta, Keiji Tanese, Kenro Hirata, Katsura Emoto, Sakiko Takeuchi, Chihiro Shiiya, Masayuki Amagai, Akiharu Kubo   +7 more
doaj   +1 more source

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

ERJ Open Research, 2018
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel   +14 more
doaj   +1 more source

Nivolumab‐induced acute tubular injury: A case report

Clinical Case Reports, 2023
Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab.
Hui‐Hsin Yang, Chia‐Wen Chang, Tai‐Di Chen   +2 more
doaj   +1 more source

Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2

IJU Case Reports, 2021
Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related
Kazunori Iwasaki, Toshitaka Shin, Toru Inoue, Tadamasa Shibuya, Kenichi Hirai, Tadasuke Ando, Hiromitsu Mimata   +6 more
doaj   +1 more source

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BMC Cancer, 2019
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma   +2 more
doaj   +1 more source

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

ESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku   +12 more
doaj   +1 more source

New-onset insulin-dependent diabetes due to nivolumab

Endocrinology, Diabetes & Metabolism Case Reports, 2018
Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events.
Ali A Zaied, Halis K Akturk, Richard W Joseph, Augustine S Lee   +3 more
doaj   +1 more source

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

Translational Oncology, 2020
We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting.
Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Rie Tokuyama, Kanako Tamai, Naoto Harigai, Yukoh Nakazaki, Wataru Obara   +11 more
doaj   +1 more source